Predictive blood-based biomarkers in epithelial ovarian cancer patients treated with carboplatin and paclitaxel with or without bevacizumab: Results from GOG-0218

PURPOSE: GOG-0218, a double-blind placebo-controlled phase III trial, compared carboplatin and paclitaxel with placebo, bevacizumab followed by placebo, or bevacizumab followed by bevacizumab in advanced epithelial ovarian cancer (EOC). Results demonstrated significantly improved progression-free su...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Secord, Angeles Alvarez, Burdett, Kirsten Bell, Owzar, Kouros, Tritchler, David, Sibley, Alexander B., Liu, Yingmiao, Starr, Mark D., Brady, J. Chris, Lankes, Heather A., Hurwitz, Herbert I., Mannel, Robert S., Tewari, Krishnansu S., O’Malley, David M., Gray, Heidi J., Bakkum-Gamez, Jamie N., Fujiwara, Keiichi, Boente, Matthew, Deng, Wei, Burger, Robert A., Birrer, Michael J., Nixon, Andrew B.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7073274/
https://ncbi.nlm.nih.gov/pubmed/31919136
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-0226
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados